Nephrology

KidneyIntelX.dkd, a first-in-class AI-enabled prognostic test, stratifies risk of DKD progression in 5 years and is specific for early stage disease.

Your daily dose of clinical news you may have missed.

SGLT-2 inhibitors were found to consistently reduce risk of CV mortality and HF events in a meta-analysis including 90 000 high-risk patients with T2D, CKD, and/or HF.

A recent American Kidney Fund survey of 300 primary care and specialty clinicians found ~15% of their patients had kidney disease of unknown origin.

This topline look at the KDIGO 2022 updated guideline highlights new recommendations for clinical use of SGLT2i, GLP-1 RA, and nonsteroidal MRA.

Find a compact sampling of 2022 chronic kidney disease research reviewed on Patient Care, chosen by the editorial staff.

Peer mentor programs can provide support for patients, especially when it comes to family planning and parenthood.

Empagliflozin achieved a decrease in risk of kidney disease progression of 28% vs placebo in the most diverse population of patients in an SGLT-2 inhibitor trial.

The findings underscore the importance of routine eGFR and UACR screening in primary care to ensure early detection of CKD and avoid related adverse outcomes.

CMHC. PCPs and cardiologists appeared to perform only half of items considered necessary for care of T2D patients in a new simulated patient study.

Studies of cardiometabolic disease pathophysiology, prevention, and treatment make science news every day. Find 12 here, at-a-glance.

Dr Maruthur, a primary care physician, helped develop the new ADA/EASD consensus report on T2D management and has suggestions.

Dr Maruthur, of Johns Hopkins Medicine, talks about how the concept of "holistic" patient care continues to expand in the management of persons with T2D.

The new consensus recommends holistic, person centered care focused on glycemic and weight management, CV risk reduction, and cardiorenal organ protection.

Nocturnal HTN is a risk factor for cardiovascular disease and stroke. How do you diagnose and treat in your practice? Test your overnight BP IQ.

Data from the pivotal phase 3 FIGARO-DKD cardiovascular outcomes trial with finerenone reaffirms the agent's dual cardiorenal risk reduction benefits in T2D-associated CKD.

Analysis of 224 000 type 2 diabetes patients over 2 decades suggests the need for "revised care pathways" that better reflect the myriad causes of persistent morbidity.

In a study of nearly 100 adults with CKD stages G3b-4 and medical comorbidity, a 12-month exercise program was found safe and improved physical functioning.

The GLP-1 RA given once weekly to T2D patients with hyperglycemia not controlled by diet and exercise lowered HbA1c to ≤6.5% in approximately half the study population.

Chronic kidney disease is underdiagnosed and undertreated across major Western countries, according to findings of the new CaReMe CKD study.

Medicare Advantage plans may cut treatment corners to avoid more costly but more effective and targeted therapy for diabetes patients.

Empagliflozin was associated with a nearly 40% reduced risk of incident renal stone disease vs placebo in a large analysis of data pooled from randomized clinical trials.

Primary care clinicians are critical to screening and caring for CKD. This "In brief" slide show reviews the 2 key lab tests used to diagnose the disease.

ADA 2022: The protective effect of finerenone on cardiovascular and renal outcomes was not affected by initial HbA1c levels or T2D duration in analysis of data from the FIDELITY pooled cohort.

ADA 2022: Tirzepatide, a GIP/GLP-1 receptor agonist, reduced a composite of kidney events in patients with type 2 diabetes and at increased cardiovascular risk in an analysis of SURPASS-4.

The USPSTF is rumored to have moved screening for chronic kidney disease to a preventive service it is actively considering and the NFK says, "It's time."

High-level results show the trial met its composite primary endpoint, lowering risk of CV death or worsening disease in patients with HFmrEF/HFpEF.

PCPs and internists accounted nationally for 57% of SGLT2i and 52% of GLP1RA prescriptions in 2020, more than any other specialty, according to new research.

The NDA for daprodustat, a novel investigational agent, is based on data from pivotal ASCEND program clinical trials.

In patients with type 2 diabetes and chronic kidney disease with and without history of CVD, finerenone was associated with improved CV and kidney outcomes.